Patent ID: 9737535
Date: 2017-08-22
CPC Classifications: A61K,A61P

Claim:
1. A method for inhibiting target of rapamycin activity in a patient, comprising administering to the patient an effective amount of 1-ethyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, in combination with an effective amount of a second active agent, wherein the second active agent is selected from the group consisting of a receptor tyrosine kinase inhibitor, a phosphoinositide 3-kinase pathway inhibitor, a serine/threonine-protein kinase and mitogen-activated protein kinase/extracellular signal-regulated protein kinase kinase pathway inhibitor, a deoxyribonucleic acid damaging agent, a deoxyribonucleic acid damage response agent, a cytoskeleton perturbagen, a protein stability inhibitor, a Bruton's tyrosine kinase inhibitor and a B-cell lymphoma-2 protein family inhibitor, wherein: the receptor tyrosine kinase inhibitor is selected from the group consisting of the phosphoinositide 3-kinase pathway inhibitor is selected from the group consisting of the serine/threonine-protein kinase and mitogen-activated protein kinase/extracellular signal-regulated protein kinase kinase pathway inhibitor is selected from the group consisting of the deoxyribonucleic acid damaging agent is selected from the group consisting of the deoxyribonucleic acid damage response agent is selected from the group consisting of the cytoskeleton perturbagen is selected from the group consisting of the protein stability inhibitor is selected from the group consisting of the Bruton's tyrosine kinase inhibitor is and the B-cell lymphoma-2 protein family inhibitor is selected from the group consisting of